Immupharma Regulatory News (IMM)

22 FEBRUARY 2016

ImmuPharma PLC

Result of GM

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce that at its General Meeting today, held in connection with the Placing and Subscription, as announced on 5 February 2016, all resolutions were duly passed.

Commenting on the announcement, Tim McCarthy, Chairman of ImmuPharma, said: "We are delighted to have received such support from our existing shareholders and new investors in this placing to fund our pivotal Phase III Lupuzor™ trial. Having recently announced that we have commenced dosing our first Lupus patients in the US, we look forward to providing regular updates on the trial through this year and 2017."

For further information please see the Company's website, www.immupharma.org, or contact:

All defined terms used in this announcement are defined, unless otherwise defined here, in the appendix to the Proposed Placing and Subscription and Notice of General Meeting announcement made on 5 February 2016.